In this bulletin, we summarize a study conducted to support FDA approval of the proposed amended TM200 skeletal marking claim. In the study, rainbow trout served as a representative freshwater-reared salmonid species. To demonstrate efficacy, the study protocol specified that the mean percentage of rainbow trout with marked vertebrae in TM200-treated tanks had to be equal to or greater than 70%.
Publication date
Type of document
Fact Sheet
Program
Species